West Announces Fourth-Quarter and Full-Year 2019 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
West Pharma (WST) Tops Q4 EPS by 10c, Revenues Beat; Initiates FY20 EPS/Revenue Mid-Point Guidance Above Consensus
February 13, 2020 6:08 AM ESTWest Pharma (NYSE: WST) reported Q4 EPS of $0.82, $0.10 better than the analyst estimate of $0.72. Revenue for the quarter came in at $470.6 million versus the consensus estimate of $451.53 million.
Fourth-Quarter and Full-Year 2019 Summary (comparisons to prior-year period)
Fourth-quarter 2019 net sales of $470.6 million grew 11.4%; organic sales growth was 12.7%; sales from a recent acquisition contributed an additional 30 basis points of growth; currency translation reduced sales by 160 basis points.Full-year 2019 net sales of $1.840 billion grew 7.1%; organic sales growth was 10.0%; sales from a recent acquisition contributed an additional 10 basis points of growth; currency translation reduced sales by 300 basis... More